精选65CNBC 财经（RSS）股市多源精选 ×2
诺和诺德上调业绩指引，华尔街仍质疑减肥药前景
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力